Patents by Inventor Glenn Michelson

Glenn Michelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING LYMPHOMA
    Publication number: 20220233533
    Abstract: Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.
    Type: Application
    Filed: January 31, 2022
    Publication date: July 28, 2022
    Inventors: Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
  • Methods for treating lymphoma
    Patent number: 11266645
    Abstract: Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: March 8, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
  • METHODS FOR TREATING LYMPHOMA
    Publication number: 20200061060
    Abstract: Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.
    Type: Application
    Filed: May 3, 2019
    Publication date: February 27, 2020
    Inventors: Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
  • METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS
    Publication number: 20170368041
    Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: July 5, 2017
    Publication date: December 28, 2017
    Inventor: Glenn Michelson
  • Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
    Patent number: 9724338
    Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: August 8, 2017
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventor: Glenn Michelson
  • METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CERTAIN HEMATOLOGIC DISORDERS
    Publication number: 20170119745
    Abstract: Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: June 3, 2016
    Publication date: May 4, 2017
    Inventors: Daniel C. Adelman, Jeffrey A. Silverman, Glenn Michelson, Caroline Dame Scatena
  • METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS
    Publication number: 20150250775
    Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 10, 2015
    Inventor: Glenn Michelson
  • METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CERTAIN HEMATOLOGIC DISORDERS
    Publication number: 20150190380
    Abstract: Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: August 15, 2014
    Publication date: July 9, 2015
    Inventors: Daniel C. Adelman, Jeffrey A. Silverman, Glenn Michelson, Caroline Dame Scatena
  • METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS
    Publication number: 20130102559
    Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: May 22, 2012
    Publication date: April 25, 2013
    Inventor: Glenn Michelson
  • METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS
    Publication number: 20110008371
    Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: December 10, 2008
    Publication date: January 13, 2011
    Inventor: Glenn Michelson
  • Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
    Publication number: 20080063642
    Abstract: Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
    Type: Application
    Filed: August 2, 2007
    Publication date: March 13, 2008
    Inventors: Daniel Adelman, Jeffrey Silverman, Glenn Michelson, Caroline Scatena